By Will Feuer


MeiraGTx Holdings said it has received a $30 million investment from French pharmaceutical company Sanofi, and said the company has been approached by multiple parties about certain assets.

MeiraGTx, a clinical-stage gene-therapy company, said Sanofi bought 4 million shares at a price of $7.50 a share. Sanofi will receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene-regulation technology for various uses, including in GLP-1 drugs.

The company said it is also actively pursuing options after multiple parties approached MeiraGTx with interest in some of the company's assets. MeiraGTx has hired Evercore as a financial advisor and Wachtell, Lipton, Rosen & Katz as legal advisor.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

10-30-23 0759ET